We offer an innovative, patient-centered way to build your health system strategy with efficiency, integrity and rigor. We proactively research and identify new drugs— often 18–24 months before FDA approval — to prioritize market opportunities and identify unmet needs prior to launch. Drug manufacturers receive real-time product launch feedback from the people treating patients, creating opportunities for course correction early in treatment.

We help design single source network level contracting agreements for limited distribution drugs (LDDs), connecting you and your products to our national network of health systems. Shields’ proprietary therapy management system, TelemetryRx® delivers industry-aggregated, real-world data from a single, standardized source.

Our drug manufacturer relationships are strategic, long-term and collaborative business partnerships. We provide a single point of contact for data contracting, eliminating the need to negotiate and manage multiple contracts with health systems while expanding access to more patients. Our experts can support your product strategy in everything from contract management and implementation to LDD pathway support and research.

Patients are at the center of the Shields Care Continuum, and that’s why our dedicated teams offer hands-on clinical management for rare and complex diseases. Because there is no handbook for rare diseases, our offering spans services like specialty drug-specific programs and designs; ETASU REMS program management and audit readiness; medical billing program solutions, and much more. Our experience includes rare conditions such as hereditary angioedema (HAE), myasthenia gravis (MG), hemophilia, and pulmonary arterial hypertension (PAH).